Home/Pipeline/Risperidone Implant

Risperidone Implant

Schizophrenia

Phase 1b/2a / Late-stageActive

Key Facts

Indication

Schizophrenia

Phase

Phase 1b/2a / Late-stage

Status

Active

Company

Delpor

About Delpor

Delpor is a private, clinical-stage biotech company pioneering once-yearly subcutaneous implant therapies for chronic diseases, with a primary focus on CNS disorders. Its proprietary, passive (non-mechanical) implant technology aims to improve patient adherence, safety, and efficacy by maintaining steady drug levels within a therapeutic window for up to a year. The company's most advanced program is a risperidone implant for schizophrenia, which has completed a Phase 1b/2a study, and it has also initiated a Phase 1 trial for a naltrexone implant for opioid addiction. Delpor's business model is centered on developing and commercializing novel therapeutic products enabled by its delivery platform.

View full company profile

Therapeutic Areas

Schizophrenia Opioid Use Disorder Spasticity Parkinson’s Disease Alzheimer’s Disease Multiple Sclerosis

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active